FTC closes probe of Resonetics’ $900M medical nitinol purchase

The acquisition would give Resonetics a leading supplier of the alloy for the medical device industry.

By Elise Reuter • Sept. 14, 2023

Bausch + Lomb seeks funding for $1.75B eye drop acquisition from Novartis

Fitch Ratings called the deal to buy the Xiidra treatment “strategically sound” even as the company’s plan to fund it would increase its leverage.

By Nick Paul Taylor • Sept. 12, 2023

Explore the Trendline➔

MedTech Dive Outlook 2022

The pandemic continues to disrupt the medical device industry early in 2022, as COVID-19 testing demand remains strong and nonemergent procedures are postponed. In this series, we look at the risks, challenges and opportunities ahead.

By MedTech Dive staff

Abbott to buy smart insulin pen cap maker Bigfoot

The planned acquisition could shift patients interested in smart pens to Abbott’s Libre CGMs, an analyst wrote.

By Elise Reuter • Sept. 6, 2023

Danaher to buy antibody supplier Abcam for $5.7B

The acquisition gives Danaher an entry into the protein consumables market, Stifel analysts said.

By Elise Reuter • Aug. 28, 2023

VC funding in medtech ticks up, raising hopes that slump has bottomed

Analysts also forecast renewed interest in M&A now that large companies have worked through a string of spinoffs.

By Nick Paul Taylor • Aug. 25, 2023

Agilent to wind down Resolution Bioscience liquid biopsy unit

The company will discontinue operations at the business it bought two years ago for $550 million.

By Susan Kelly • Aug. 21, 2023

Bruker to buy PhenomeX and its cell research tools for $108M

The life science tools sector is ripe for consolidation, according to analysts at TD Cowen.

By Susan Kelly • Aug. 18, 2023

Labcorp scoops up Tufts Medicine outreach lab, continuing buying spree

As the laboratory services giant continues its acquisition streak, hundreds of employees will be let go at the Boston-based academic health system.

By Susan Kelly • Aug. 15, 2023

Cooper scraps $875M takeover of Cook Medical business after FTC investigation

The FTC said ending the planned acquisition “ensures that critical reproductive health markets remain competitive.” 

By Nick Paul Taylor • Aug. 2, 2023

Baxter progresses with planned kidney care spinoff, expects biopharma solutions sale this quarter

The company expects hospital spending to increase in the second half of the year amid rising procedure volumes and a stabilizing supply chain. 

By Elise Reuter • July 27, 2023

Teleflex to expand urology portfolio with $600M acquisition

The company reached an agreement to buy Palette Life Sciences, as it looks to grow through acquisitions.

By Elise Reuter • July 26, 2023

Big Health buys Limbix to add adolescent depression app to digital therapeutic portfolio

The phone-based treatment, SparkRx, uses self-guided, cognitive behavioral therapy to teach skills such as mood tracking.

By Nick Paul Taylor • July 18, 2023

Illumina hit by EU with maximum €432M fine for Grail acquisition

The European Commission called Illumina’s closing of the deal without its approval an “unprecedented” move that undermines its system for regulating the competitive landscape.

By Susan Kelly • July 12, 2023

Coloplast to pay $1.2B upfront to buy fish skin wound care business Kerecis

Kerecis’ fish skin biologic, which aids tissue regeneration, helped drive the company’s sales to $74.5 million last year.

By Nick Paul Taylor • July 10, 2023

ResMed buys Somnoware to expand sleep management software portfolio

The maker of sleep and respiratory care devices said it plans to retain all of Somnoware’s staff and maintain its open platform for patient testing and treatment.

By Nick Paul Taylor • July 7, 2023

Bausch + Lomb bulks up OTC business with J&J deal

The eye care company has become an active acquirer under new CEO Brent Saunders, buying an eye drop product line one week after purchasing several medicines from Novartis.

By Ned Pagliarulo • July 6, 2023

Thermo Fisher to buy real-world evidence company CorEvitas for $913M

The acquisition is expected to complement Thermo Fisher’s clinical research business and become “immediately accretive” to its adjusted earnings per share.

By Elise Reuter • July 6, 2023

FTC proposes updates to merger review that could slow healthcare dealmaking

A new rule proposed by antitrust regulators would ask companies to provide additional information about planned mergers to help the Federal Trade Commission keep pace with increased deal volume and complexity.

By Emily Olsen • June 28, 2023

Restor3d inks Conformis buyout, adding hip and knee implants to portfolio

Restor3d, which makes 3D-printed devices for spine, ankle and upper extremity procedures, is buying Conformis at a 96% premium. 

By Nick Paul Taylor • June 27, 2023

BD plans $540M sale of surgical instrumentation platform to Steris

The divestiture is part of BD’s strategy to simplify its portfolio and focus on higher-growth markets.

By Peter Green • Updated June 20, 2023

Glass Lewis, joining ISS, supports activist’s candidates for Masimo board

Saying it has “rarely” seen a circumstance where the “need for direct representation of a large shareholder in the boardroom was so apparent,” the proxy advisory firm backed Politan Capital’s bid for two board seats.

By Susan Kelly • June 16, 2023

As Illumina’s deSouza departs, will Grail go next?

The CEO’s resignation could signal a change of direction, as anti-trust regulators order Illumina to divest the liquid biopsy unit.

By Susan Kelly • June 12, 2023

Merit Medical buys two dialysis catheter lines for $132.5M combined

The acquisitions are expected to boost the Utah-based device maker’s annual revenue by about $30 million.

By Susan Kelly • June 9, 2023

SunMed agrees to $110M takeover of Avanos’ respiratory health unit, continuing M&A spree

Avanos, whose competitors include Stryker and Medline Industries, is selling the unit to narrow its focus on areas where it can succeed.

By Nick Paul Taylor • June 9, 2023

Novo Nordisk says in talks to acquire French device-maker Biocorp for $165M

The offer per share is about 20% more than Biocorp’s closing stock price on June 2. The two companies plan to focus on drug delivery solutions for chronic diseases, such as diabetes.

By Elise Reuter • Updated June 6, 2023